18F-DCFPyL PET对不良中危或高危前列腺癌分期及治疗的影响
该前瞻性研究纳入108例活检证实、未治疗的不良中危或高危前列腺癌患者,比较18F-DCFPyL PET/CT或PET/MRI与常规影像(骨扫描和CT±多参数MRI)在初始分期中的诊断效能,并评估PET后治疗方案的改变。结果显示PET对淋巴结转移和远处转移的检出率均高于常规影像,使40%患者分期改变、22%患者治疗改变,且不确定发现更少。
要点
- 18F-DCFPyL PET对淋巴结转移检出率34%(37/108),常规影像11%(12/108),P < .001。
- PET对远处转移检出率22%(24/108),常规影像10%(11/108),P = .02。
- PET使40%(43/108)患者分期改变、22%(24/108)患者治疗改变。
核心结论
- 在常规影像(骨扫描和CT±多参数MRI)之后行18F-DCFPyL PET初始分期,较单独常规影像可检出更多淋巴结和远处转移,并使22%的患者治疗改变。
研究设计与样本
- 前瞻性研究纳入108例活检证实、未治疗、不良中危或高危前列腺癌患者(中位年龄66岁,IQR 61-73岁),于2018年5月至2020年12月期间行18F-DCFPyL PET/CT或PET/MRI。
诊断标准与关键数值
- 以包括组织病理学分析、相关影像和/或临床及生化随访的复合参考标准,比较常规影像与PET的转移部位;PET和常规影像对淋巴结转移检出率分别为34%(37/108)和11%(12/108)(P < .001),对远处转移检出率分别为22%(24/108)和10%(11/108)(P = .02);PET不确定发现1/108(1%),常规影像29/108(27%)。
临床应用与阅片要点
- 原文结论指出,常规影像后行18F-DCFPyL PET初始分期有助于检出更多淋巴结和远处转移,并使22%的患者治疗改变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Data regarding 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) PET in primary staging of prostate cancer (PCa) are limited. Purpose To compare the performance of 18F-DCFPyL PET/CT or PET/MRI (PET) with bone scan and CT with or without multiparametric MRI (hereafter, referred to as conventional imaging) in the initial staging of men with unfavorable intermediate or high-risk PCa and to assess treatment change after PET. Materials and Methods This prospective study evaluated men with biopsy-proven, untreated, unfavorable intermediate or high-risk PCa with 0 to four metastases or equivocal for extensive metastases (more than four) who underwent PET between May 2018 and December 2020. The diagnostic performance of PET in detecting pelvic nodal and distant metastases was compared with conventional imaging alone. Metastatic sites at conventional imaging and PET were compared with a composite reference standard including histopathologic analysis, correlative imaging, and/or clinical and biochemical follow-up. The intended treatment before PET was compared with the treatment plan established after performing PET. Detection rate, sensitivity, and specificity of conventional imaging and PET were compared by using McNemar exact test on paired proportions. Results The study consisted of 108 men (median age, 66 years; IQR, 61-73 years) with no metastases (n = 84), with oligometastases (four or fewer metastases; 22 men), or with equivocal findings for extensive metastases (n = 2). Detection rates at PET and conventional imaging for nodal metastases were 34% (37 of 108) and 11% (12 of 108) (P < .001), respectively, and those for distant metastases were 22% (24 of 108) and 10% (11 of 108) (P = .02), respectively. PET altered stage in 43 of 108 (40%) and treatment in 24 of 108 (22%) men. The most frequent treatment change was from systemic to local-regional therapy in 10 of 108 (9%) and from local-regional to systemic therapy in nine of 108 (8%) men. Equivocal findings were encountered less frequently with PET (one of 108; 1%) than with conventional imaging (29 of 108; 27%). Conclusion Initial staging with 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) PET after conventional imaging (bone scan and CT with or without multiparametric MRI) helped to detect more nodal and distant metastases than conventional imaging alone and changed treatment in 22% of men. Clinical trial registration no. NCT03535831, NCT03718260 © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Jadvar in this issue.
引用
- Basso Dias, Finelli, Bauman, et al. Impact of 18F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer. Radiology. 2022. PMID: 35608445. doi:10.1148/radiol.211836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。